Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$53.56 - $87.24
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.75M
Market Cap
$16.40B
Enterprise Value$11.16B
Total Cash (Recent Filing)$2.42B
Total Debt (Recent Filing)$42.41M
Price to Earnings (P/E)19.1
Beta0.54
Next Earnings
Nov 04, 2025EPS Estimate
1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding195,276,140
10 Day Avg. Volume1,807,038
30 Day Avg. Volume1,751,833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit2.62
Enterprise Value/Ebitda8.23
Forecast
1Y Price Target
$83.17Price Target Upside-1.97% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
EarningsINCY reported strong results with beats for Jakafi, Opzelura, and Niktimvo leading to total revenues that were 6% above consensus.
Product PerformanceThe early Niktimvo launch showed significant strength, leading to increased sales estimates for 2025 and 2030.
Revenue GrowthStrong growth for assets like Niktimvo starts to make analysts more confident in the asset's commercial potential.
Bears Say
Cash FlowIncyte's modest cash positioning could be growth-limiting for transactions.
Pipeline DelaysPipeline delays, including the JAK2V617Fi data delay, give pause to the company's longer-term outlook.
Revenue DependencyJakafi's late loss of exclusivity in 2028 poses a significant challenge, as it constitutes approximately 65% of total revenues.
Incyte News
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $53.56 and its highest was $87.24 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $16.40B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Nov 04, 2025 which is in 68 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Jul 29, 2025. The company reported $1.572 earnings per share for the quarter, beating the consensus estimate of $1.401 by $0.171.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Overvalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.58.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 195,276,140 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.572 in its last earnings report, beating expectations of $1.401. Following the earnings report the stock price went up 10.291%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in INCY
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$83.17 (-1.97% Downside)
$83.17 (-1.97% Downside)
Blogger Sentiment
Bullish
INCY Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 876.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.91%
12-Months-Change
Fundamentals
Return on Equity
24.30%
Trailing 12-Months
Asset Growth
24.87%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation (INCY) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to treat serious diseases, primarily cancer and other hematologic disorders. The company operates in the oncology sector with a strong emphasis on targeted therapies and has a portfolio that includes both approved drugs and a pipeline of investigational products. Key products include Jakafi (ruxolitinib), a treatment for certain types of blood cancers, and other therapeutic candidates aimed at various malignancies and immunological conditions.
INCY Company Deck
INCY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and successful product launches, particularly for Jakafi, Opzelura, and Niktimvo. However, increased R&D expenses and a delay in the regulatory timeline for V617F Phase I data were noted as challenges.View all INCY earnings summariesINCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$83.17
▼(-1.97% Downside)
Technical Analysis
Ownership Overview
15.70% Insiders
22.90% Mutual Funds
0.60% Other Institutional Investors
34.48% Public Companies and Individual Investors